Selexis CHO Cells in Suspension-1

Archives 2018

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

DECEMBER 3, 2018
6 min read

KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board

Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics...

Read More
OCTOBER 18, 2018
3 min read

Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform

Effort Designed to Safely and Efficiently Speed Drug Candidates into the Clinic

Geneva, Switzerland, October 18, 2018 –...

Read More
SEPTEMBER 26, 2018
3 min read

Selexis and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic

Selexis SUREtechnology Platform™ Successfully Expresses Hoba’s HB-086 in CHO Cells

Geneva, Switzerland, and Copenhagen,...

Read More
SEPTEMBER 13, 2018
2 min read

Meet with Selexis Scientific and Business Leaders at Several Upcoming Industry Conferences and Events

Geneva, Switzerland, September 13, 2018Selexis SA, a pioneering life sciences company and a global leader in...

Read More
JULY 10, 2018
3 min read

Symphogen A/S and Selexis Expand Relationship as Symphogen Advances its Monoclonal Antibody (mAb) Mixture Pipeline

Geneva, Switzerland, 10 July 2018Selexis SA today announced that under the terms of an earlier commercial license...

Read More
JUNE 12, 2018
4 min read

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

Program is on track for clinical trial start in H2 2019 

TORONTO, ONTARIO and CAMBRIDGE, MA – June 12, 2018 – ProMIS...

Read More
MAY 31, 2018
4 min read

IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines

Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate...

Read More
MAY 17, 2018
3 min read

Selexis Named One of the “Best Companies to Work for in Switzerland 2018”

Geneva, Switzerland, 17 May 2018Selexis SA, a pioneering life sciences company and a global leader in mammalian cell...

Read More
MAY 7, 2018
3 min read

Swiss Biotech Association Honors Selexis Among Its Inaugural Group of Swiss Biotech Success Stories

Company Among Five 2018 Laureates Recognized for Important, Sustainable Contributions to the Biotech Industry in...

Read More
APRIL 11, 2018
3 min read

Selexis SA Strengthens Cell Line Development Services for Partners with Key Strategic Hires and Investment in State-of-the-Art Laboratory Equipment

Company’s Growth Momentum Continues Following Signing of 100th Commercial License Agreement 

Geneva, Switzerland, 11...

Read More
MARCH 7, 2018
2 min read

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen

Geneva,...

Read More
FEBRUARY 26, 2018
3 min read

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Expanded Partnership Leverages Selexis’ Expertise in Recombinant Therapeutic Development Solutions

Geneva, Switzerland,...

Read More
JANUARY 17, 2018
3 min read

Selexis SA Appoints Alberto Garotti as Chief Financial Officer

Seasoned Executive to Guide Company’s Financial Strategy Amid Strong Year-Over-Year Growth

Geneva, Switzerland, 17...

Read More
JANUARY 5, 2018
3 min read

Selexis SA to Participate at Several Upcoming Industry Conferences

Geneva, Switzerland, 5 January 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More